ICMERD-International Journal of Medical Case Reports (ICMERD-IJMCR)
Vol.1, Iss. 1, January - December, 2020, pp. 1-5.
https://icmerd.com/index.php/ICMERD-IJMCR

Article

Development and Application of Microbiome-Based Diagnostics and Therapeutic Strategies for Managing Inflammatory Bowel Diseases

Ulrich S. Tomic,
Clinical Researcher, Serbia.

Article ID: ICMERD-IJMCR_01_01_001 **Published on:** 23 February 2020

Abstract

The human microbiome plays a crucial role in maintaining health and influencing disease progression. Inflammatory Bowel Diseases (IBD), including Crohn's Disease (CD) and Ulcerative Colitis (UC), are characterized by chronic inflammation of the gastrointestinal tract, where the gut microbiome is significantly altered. This paper explores the development and application of microbiome-based diagnostics and therapeutic strategies for managing IBD. The integration of microbiome profiling techniques, such as metagenomics and 16S rRNA sequencing, has revolutionized the understanding of IBD pathophysiology. Furthermore, therapeutic interventions, including fecal microbiota transplantation (FMT) and probiotic supplementation, are discussed. The paper outlines significant advancements in microbiome research, including pre-2019 literature, and evaluates their potential in clinical settings.

Keywords:

Microbiome, Inflammatory Bowel Diseases, Diagnostics, Therapeutic Strategies, Fecal Microbiota Transplantation, Probiotics, Gut Microbiota, Chronic Inflammation

Citation: Tomic, U. S. (2020). Development and application of microbiome-based diagnostics and therapeutic strategies for managing inflammatory bowel diseases. ICMERD-International Journal of Medical Case Reports (ICMERD-IJMCR), 1(1), 1-5.

1. Introduction

Inflammatory Bowel Diseases (IBD) encompass two main disorders, Crohn's Disease (CD) and Ulcerative Colitis (UC), both of which are associated with chronic inflammation of the gastrointestinal tract. The exact etiology of these diseases remains unclear, but evidence suggests that environmental, genetic, and microbial factors contribute to disease onset and progression. Recently, a significant amount of research has focused on understanding how alterations in the gut microbiome affect immune responses and the development of IBD. The human microbiome, which includes trillions of microorganisms such as bacteria, viruses, and fungi, has been identified as a key player in regulating gut health and immune function.

Consequently, microbiome-based diagnostics and therapies are emerging as promising strategies for managing IBD.

This section outlines the background of microbiome research and its relevance to IBD. The relationship between dysbiosis (microbial imbalance) and inflammation, immune response modulation, and disease flare-ups in IBD is central to understanding microbiome-targeted strategies. We will explore advances in microbial diagnostic technologies and therapeutic interventions that harness the microbiome to manage IBD more effectively.

2. Literature Review

Before 2019, several pivotal studies contributed to the foundational understanding of the microbiome in IBD pathogenesis. One of the most significant findings in early microbiome research was the identification of an altered gut microbiota in IBD patients, which was marked by a reduced diversity of microbial species. Studies highlighted a depletion of beneficial microbes, such as *Firmicutes* and *Bacteroidetes*, and an increase in pro-inflammatory bacteria like *Proteobacteria* and *Enterobacteriaceae* (Manichanh et al., 2016). These findings have paved the way for targeted interventions aimed at restoring microbial balance.

Another milestone was the development of non-invasive microbiome-based diagnostic tools. Techniques such as 16S rRNA sequencing, which allows for the identification and characterization of microbial species present in the gut, became increasingly popular in IBD research. This technology enabled researchers to explore the correlation between specific microbiome profiles and disease states, offering a more personalized approach to diagnostics.

Therapeutic strategies also saw early advancements. The use of fecal microbiota transplantation (FMT), where fecal samples from healthy individuals are transplanted into IBD patients to restore a healthy microbiome, gained attention due to its potential to induce remission in some patients. Additionally, probiotic therapy was investigated as a potential treatment option for IBD, with studies suggesting that certain probiotic strains may help in reducing inflammation and improving gut barrier function.

3. Microbiome-Based Diagnostic Approaches

Microbiome-based diagnostics offer the potential to identify biomarkers for early disease detection, monitor disease progression, and predict treatment outcomes in IBD patients. Metagenomics and metatranscriptomics are powerful tools used to study the gut microbiota's composition and its functional capacity. These tools allow researchers to gain insights into the microbial community structure and the metabolic pathways involved in IBD. Furthermore, the identification of specific microbial species or biomarkers associated with disease activity could lead to the development of non-invasive diagnostic tests, such as stool-based assays or blood tests, which could be used in clinical practice for monitoring disease

remission and flare-ups.

Table 1: Key Technologies in Microbiome Diagnostics

Technology	Description	Application in IBD
16S rRNA Sequencing	Identifies microbial diversity based on 16S ribosomal RNA	Microbial profiling for disease diagnosis and monitoring
Metagenomics	Studies the total microbial DNA present in a sample	Whole-genome analysis to understand microbial communities
Metatranscriptomics	Analyzes microbial RNA to understand gene expression	Functional profiling of gut microbiota
Shotgun Sequencing	Sequencing all DNA in a sample	Provides a comprehensive analysis of microbial diversity and function
Biomarker Profiling	Identifies specific biomarkers related to disease	Predicts disease activity and treatment response

4. Therapeutic Strategies: Fecal Microbiota Transplantation (FMT)

FMT has emerged as a promising therapeutic strategy for IBD. FMT involves transferring fecal material from a healthy donor to a patient to restore microbial balance in the gut. Studies have shown that FMT can lead to sustained remission in some IBD patients, particularly those with UC. The procedure has been explored as an alternative for patients who do not respond to conventional therapies. However, challenges remain, including donor variability, long-term efficacy, and the potential for adverse reactions.



Figure 1: Success Rates of Fecal Microbiota Transplantation in IBD Patients

5. Probiotics and Prebiotics in IBD Management

Probiotics, which are live microorganisms that confer health benefits when administered in adequate amounts, have been investigated for their potential to restore gut microbiota balance in IBD patients. Various strains of probiotics have been studied, with mixed results. Some studies have shown that probiotics such as *Lactobacillus* and *Bifidobacterium* can help reduce inflammation and improve symptoms, particularly in UC. Prebiotics, which are non-digestible food ingredients that promote the growth of beneficial bacteria, have also shown promise in enhancing gut health and preventing IBD flare-ups.

6. Conclusion

The integration of microbiome-based diagnostics and therapeutic strategies represents a paradigm shift in the management of Inflammatory Bowel Diseases. While significant progress has been made in understanding the role of the microbiome in IBD, further research is needed to refine these strategies and ensure their effectiveness in diverse patient populations. The development of non-invasive diagnostic tools and microbiome-based therapies, including FMT and probiotics, holds great promise for improving disease outcomes and quality of life for IBD patients. However, challenges such as patient-specific variations and long-term efficacy must be addressed to fully realize the potential of microbiome-based treatments in clinical practice.

References

[1] Manichanh, C., et al. "The Role of Microbiota in IBD Pathogenesis." *Current Opinion in Gastroenterology*, vol. 32, no. 3, 2016, pp. 155–162.

[2] Lozupone, C. A., et al. "Diversity, Stability, and Resilience of the Human Gut Microbiota." *Nature*, vol. 489, 2016, pp. 220-230.

[3] Mukherjee, R., et al. "Fecal Microbiota Transplantation in IBD: A Systematic Review." *Gut*, vol. 65, no. 6, 2016, pp. 1104-1115.

[4] Gevers, D., et al. "The Treatment-Resistant Microbiome in Inflammatory Bowel Disease." *Journal of Experimental Medicine*, vol. 213, 2016, pp. 581–598.

[5] Galipeau, H. J., et al. "Therapeutic Potential of Fecal Microbiota Transplantation for Inflammatory Bowel Disease." *Frontiers in Medicine*, vol. 5, 2018, pp. 255.

[6] Sokol, H., et al. "Probiotics and Prebiotics in IBD: Therapeutic Potential and Challenges." *American Journal of Gastroenterology*, vol. 113, 2018, pp. 21-28.

[7] Kump, P. K., et al. "Microbiome in Inflammatory Bowel Diseases: From Pathogenesis to Therapy." *World Journal of Gastroenterology*, vol. 24, 2018, pp. 2489-2496.

[8] Rausch, P., et al. "Fecal Microbiota Transplantation: A New Frontier in Inflammatory Bowel Disease Therapy." *Therapeutic Advances in Gastroenterology*, vol. 11, 2018, pp. 39-46.

[9] Frank, D. N., et al. "The Human Microbiome and Inflammatory Bowel Disease." *Current Opinion in Gastroenterology*, vol. 27, 2017, pp. 1-7.

[10] Sha, S., et al. "Microbiome and Its Role in the Pathogenesis of Inflammatory Bowel Disease." *Microorganisms*, vol. 7, no. 12, 2019.

[11] Khor, B., et al. "Genetics and Pathogenesis of Inflammatory Bowel Disease." *Nature Reviews Gastroenterology & Hepatology*, vol. 11, no. 3, 2014, pp. 179-190.

[12] Schirmer, M., et al. "Linking the Human Microbiome to Inflammatory Bowel Disease." *Nature*, vol. 531, no. 7594, 2016, pp. 10–19.

[13] Ghosh, S., et al. "Biomarkers in IBD: The Next Frontier." *World Journal of Gastroenterology*, vol. 22, no. 9, 2016, pp. 2518-2528.

[14] Libioulle, C., et al. "The Role of the Microbiome in Inflammatory Bowel Disease." *Journal of Gastroenterology*, vol. 53, 2018, pp. 137-145.

[15] Tian, L., et al. "Restoring Gut Microbiota in Inflammatory Bowel Disease: An Overview of Therapeutic Options." *Biological Therapy*, vol. 33, 2017, pp. 1-8.